BioMarin Pharmaceutical (BMRN) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 47.4 | 265.4 | 306.8 | 650.5 | 572.9 | 482.5 | ||
| Changes by years, y/y, % | -43% | +459% | +16% | +112% | -12% | +46.9% | |||
BioMarin Pharmaceutical. EBITDA US GAAP, bln rub
BioMarin Pharmaceutical. EBITDA US GAAP, changes, %
BioMarin Pharmaceutical. EBITDA US GAAP, sum by quarters, bln rub
BioMarin Pharmaceutical (BMRN) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | 263.0 | 319.1 | -5.26 | -3.94 | 172.6 | 482.5 | |
| Changes by years, y/y, % | +93% | +97% | -103% | -102% | -34% | |||
| Changes by quarters, q/q, % | +35% | +21% | -102% | -25% | -4 483% | |||